D-Day approaching for Cell Therapeutics' pixantrone
On 10 February 2010, members of the FDA's Oncologic Drugs Advisory Committee will meet to hear testimony and debate whether or not to approve Cell Therapeutics' application to market pixantrone, the company's experimental drug to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
For Cell Therapeutics, it's fairly safe to say that the fate of the company relies on pixantrone's approval, which while not a sure thing, is nonetheless very likely. The drug has been proven to be fairly effective in tumor reduction and it seems to have a low cardiac toxicity profile. It has not been shown to extend patients' lives; fortunately for Cell Therapeutics, and perhaps not so fortunately for future patients, FDA approval doesn't hinge on this all-important factor.
More on pixantrone from Cell Therapeutics.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
